SE0104333D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104333D0
SE0104333D0 SE0104333A SE0104333A SE0104333D0 SE 0104333 D0 SE0104333 D0 SE 0104333D0 SE 0104333 A SE0104333 A SE 0104333A SE 0104333 A SE0104333 A SE 0104333A SE 0104333 D0 SE0104333 D0 SE 0104333D0
Authority
SE
Sweden
Prior art keywords
sup
well
therapeutic agents
racemates
prodrugs
Prior art date
Application number
SE0104333A
Other languages
English (en)
Swedish (sv)
Inventor
Alstermark Eva-Lotte Lindstedt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104333A priority Critical patent/SE0104333D0/xx
Publication of SE0104333D0 publication Critical patent/SE0104333D0/xx
Priority to MXPA04005992A priority patent/MXPA04005992A/es
Priority to IL16237802A priority patent/IL162378A0/xx
Priority to CNB028281225A priority patent/CN100343229C/zh
Priority to NZ533365A priority patent/NZ533365A/en
Priority to BR0215090-5A priority patent/BR0215090A/pt
Priority to ES02788144T priority patent/ES2324025T3/es
Priority to US10/499,042 priority patent/US7276539B2/en
Priority to AT02788144T priority patent/ATE428691T1/de
Priority to KR10-2004-7009348A priority patent/KR20040068589A/ko
Priority to EP02788144A priority patent/EP1458677B1/en
Priority to PL02370623A priority patent/PL370623A1/xx
Priority to JP2003552714A priority patent/JP3810770B2/ja
Priority to TW091136517A priority patent/TW200410678A/zh
Priority to HK05100665.9A priority patent/HK1068866B/en
Priority to DE60232018T priority patent/DE60232018D1/de
Priority to HU0402093A priority patent/HUP0402093A3/hu
Priority to AU2002352426A priority patent/AU2002352426A1/en
Priority to RU2004117776/04A priority patent/RU2004117776A/ru
Priority to UA20040604534A priority patent/UA80407C2/uk
Priority to CA002470066A priority patent/CA2470066C/en
Priority to PCT/GB2002/005743 priority patent/WO2003051826A1/en
Priority to ARP020105003A priority patent/AR038046A1/es
Priority to IS7303A priority patent/IS7303A/is
Priority to ZA200404585A priority patent/ZA200404585B/en
Priority to CO04068143A priority patent/CO5590908A2/es
Priority to NO20043084A priority patent/NO20043084L/no
Priority to JP2006077296A priority patent/JP2006241162A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
SE0104333A 2001-12-19 2001-12-19 Therapeutic agents SE0104333D0 (sv)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005743 WO2003051826A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
JP2003552714A JP3810770B2 (ja) 2001-12-19 2002-12-18 ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体
HK05100665.9A HK1068866B (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
CNB028281225A CN100343229C (zh) 2001-12-19 2002-12-18 作为选择性PPAR－α激动剂的3－苯基－2－芳基烷基硫代丙酸衍生物
NZ533365A NZ533365A (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
BR0215090-5A BR0215090A (pt) 2001-12-19 2002-12-18 Composto, enanciÈmero (r) ou enanciÈmero (s) de um composto, formulação farmacêutica, método para tratar ou prevenir distúrbios lipìdicos (dislipidemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou prevenir diabetes de tipo 2, processo para preparar um composto, e, composição farmacêutica
ES02788144T ES2324025T3 (es) 2001-12-19 2002-12-18 Derivados del acido 3-fenil-2-arilalquiltiopropionico como agonistas selectivos de ppar-alfa.
US10/499,042 US7276539B2 (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
AT02788144T ATE428691T1 (de) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha
KR10-2004-7009348A KR20040068589A (ko) 2001-12-19 2002-12-18 Ｐｐａｒ-알파의 선택적 효능제로서3-페닐-2-아릴알킬티오프로피온산 유도체
EP02788144A EP1458677B1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
PL02370623A PL370623A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
MXPA04005992A MXPA04005992A (es) 2001-12-19 2002-12-18 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
TW091136517A TW200410678A (en) 2001-12-19 2002-12-18 Therapeutic agents
IL16237802A IL162378A0 (en) 2001-12-19 2002-12-18 3-Phenyl-2-arylalkylthiopropionic acid derivativesas selective agonists of ppar-al-pha
DE60232018T DE60232018D1 (de) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionsäure-derivate als selektive agonisten von ppar-alpha
HU0402093A HUP0402093A3 (en) 2001-12-19 2002-12-18 3-phenyl-2-phenethylthio-propionic acid derivatives as selective agonists of ppar-alpha, their preparation and pharmaceutical compositions containing them
AU2002352426A AU2002352426A1 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
RU2004117776/04A RU2004117776A (ru) 2001-12-19 2002-12-18 Производные 3-фенил-2-арилалкилтиопропионовой кислоты в качестве селективных антагонистов ppar-альфа
UA20040604534A UA80407C2 (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of parp-alpha
CA002470066A CA2470066C (en) 2001-12-19 2002-12-18 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
ARP020105003A AR038046A1 (es) 2001-12-19 2002-12-19 Derivados de acidos 3-fenil-2-arilalquiltiopropionicos moduladores de ppar alfa
IS7303A IS7303A (is) 2001-12-19 2004-06-08 3-fenýl-2-arýlalkýlþíóprópíónsýruafleiður sem valvís gerandefni PPAR-ALFA
ZA200404585A ZA200404585B (en) 2001-12-19 2004-06-09 3-Phenyl-2-arylalkylthiopropionic acid derivativesas selective agonists of PPAR-alpha.
CO04068143A CO5590908A2 (es) 2001-12-19 2004-07-16 Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa
NO20043084A NO20043084L (no) 2001-12-19 2004-07-16 3-fenyl-2-arylalkyltiopropionsyre derivater som selektive agnoister av PPAR-ALPHA
JP2006077296A JP2006241162A (ja) 2001-12-19 2006-03-20 ＰＰＡＲαの選択的アンタゴニストとしての３−フェニル−２−アリールアルキルチオプロピオン酸誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104333D0 true SE0104333D0 (sv) 2001-12-19

Family

ID=20286432

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104333A SE0104333D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (26)

Country Link
US (1) US7276539B2 (https=)
EP (1) EP1458677B1 (https=)
JP (2) JP3810770B2 (https=)
KR (1) KR20040068589A (https=)
CN (1) CN100343229C (https=)
AR (1) AR038046A1 (https=)
AT (1) ATE428691T1 (https=)
AU (1) AU2002352426A1 (https=)
BR (1) BR0215090A (https=)
CA (1) CA2470066C (https=)
CO (1) CO5590908A2 (https=)
DE (1) DE60232018D1 (https=)
ES (1) ES2324025T3 (https=)
HU (1) HUP0402093A3 (https=)
IL (1) IL162378A0 (https=)
IS (1) IS7303A (https=)
MX (1) MXPA04005992A (https=)
NO (1) NO20043084L (https=)
NZ (1) NZ533365A (https=)
PL (1) PL370623A1 (https=)
RU (1) RU2004117776A (https=)
SE (1) SE0104333D0 (https=)
TW (1) TW200410678A (https=)
UA (1) UA80407C2 (https=)
WO (1) WO2003051826A1 (https=)
ZA (1) ZA200404585B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375074A1 (en) 2002-06-20 2005-11-14 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314131D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process
GB0427701D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Therapeutic agents
AU2008221673B2 (en) * 2007-03-08 2013-03-28 Albireo Ab 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
WO1999029640A2 (en) 1997-12-05 1999-06-17 Eisai Co., Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
NZ515086A (en) * 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
TW574193B (en) 1999-12-03 2004-02-01 Astrazeneca Ab Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses
SE9904421D0 (sv) 1999-12-03 1999-12-03 Astra Ab New compounds
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
SE0101978D0 (sv) 2001-06-01 2001-06-01 Astrazeneca Ab New compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
TWI331143B (en) * 2001-09-08 2010-10-01 Astrazeneca Uk Ltd Benzothiadiazepine derivatives, process for preparing them, and pharmaceutical composition comprising them
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
PL375074A1 (en) 2002-06-20 2005-11-14 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
JP2006241162A (ja) 2006-09-14
CA2470066C (en) 2007-04-10
EP1458677B1 (en) 2009-04-15
CN100343229C (zh) 2007-10-17
HUP0402093A2 (hu) 2005-02-28
CO5590908A2 (es) 2005-12-30
WO2003051826A1 (en) 2003-06-26
MXPA04005992A (es) 2004-09-27
HUP0402093A3 (en) 2008-08-28
AR038046A1 (es) 2004-12-22
NZ533365A (en) 2006-05-26
CN1620430A (zh) 2005-05-25
EP1458677A1 (en) 2004-09-22
AU2002352426A1 (en) 2003-06-30
JP2005511785A (ja) 2005-04-28
ATE428691T1 (de) 2009-05-15
US7276539B2 (en) 2007-10-02
KR20040068589A (ko) 2004-07-31
DE60232018D1 (de) 2009-05-28
ES2324025T3 (es) 2009-07-29
UA80407C2 (en) 2007-09-25
RU2004117776A (ru) 2006-01-10
HK1068866A1 (en) 2005-05-06
ZA200404585B (en) 2005-10-26
CA2470066A1 (en) 2003-06-26
NO20043084L (no) 2004-07-16
IL162378A0 (en) 2005-11-20
PL370623A1 (en) 2005-05-30
IS7303A (is) 2004-06-08
US20050215630A1 (en) 2005-09-29
BR0215090A (pt) 2004-11-16
JP3810770B2 (ja) 2006-08-16
TW200410678A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
SE0104334D0 (sv) Therapeutic agents
TW200508180A (en) Therapeutic agents
SE0302487D0 (sv) Novel compounds
SE9903760D0 (sv) New compounds
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
SE0302324D0 (sv) Novel compounds
SE9904176D0 (sv) New use
MY137156A (en) Dual nk1/nk3 derivatives
SE0302323D0 (sv) Novel compounds
DE69100079D1 (de) Naphthalin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
UA66852C2 (uk) Похідні та аналоги 3-арилпропіонової кислоти, спосіб їх отримання, фармацевтична композиція (варіанти) та спосіб профілактики та/або лікування асоційованих з резистентністю до інсуліну клінічних станів
BR0313407A (pt) Novo uso de derivados de benzotiazol
DE60107820D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
SE9903997D0 (sv) New compounds
SE0302756D0 (sv) Novel Compounds
SE0104333D0 (sv) Therapeutic agents
IL166103A0 (en) Pyrrolidine derivatives and their use
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
SE9900190D0 (sv) New compounds
SE0201936D0 (sv) Therapeutic agents
SE0102640D0 (sv) Novel compounds
DE60103035D1 (de) Neue verwendung von phenylheteroalkylamin-derivaten
TW200502202A (en) Therapeutic agents